ARQT stock icon

Arcutis Biotherapeutics
ARQT

$8.63
7.6%
 

About: Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate ZORYVE roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.

Employees: 296

0
Funds holding %
of 6,689 funds
0
Analysts bullish %
of 9 analysts
0
News positive %
of 6 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

500% more funds holding in top 10

Funds holding in top 10: 1 [Q4 2023] → 6 (+5) [Q1 2024]

278% more capital invested

Capital invested by funds: $327M [Q4 2023] → $1.24B (+$910M) [Q1 2024]

124% more first-time investments, than exits

New positions opened: 56 | Existing positions closed: 25

28% more repeat investments, than reductions

Existing positions increased: 51 | Existing positions reduced: 40

23% more funds holding

Funds holding: 132 [Q4 2023] → 163 (+31) [Q1 2024]

1.25% more ownership

Funds ownership: 107.29% [Q4 2023] → 108.54% (+1.25%) [Q1 2024]

42% less call options, than puts

Call options by funds: $4.93M | Put options by funds: $8.55M

Research analyst outlook

9 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$8
7%
downside
Avg. target
$14.22
65%
upside
High target
$18
109%
upside

9 analyst ratings

positive
89%
neutral
11%
negative
0%
Needham
Serge Belanger
109%upside
$18
Buy
Maintained
15 May 2024
Mizuho
Uy Ear
109%upside
$18
Buy
Maintained
15 May 2024
Needham
Serge Belanger
85%upside
$16
Buy
Reiterated
12 Apr 2024
Goldman Sachs
Jonathan Block
27%upside
$11
Neutral
Maintained
28 Feb 2024
Mizuho
Uy Ear
97%upside
$17
Buy
Reiterated
28 Feb 2024

Financial journalist opinion

Based on 6 articles about ARQT published over the past 30 days